Previously, Ruiz et al. (2005; 2009) reported that SPL treatment improves liver injury in ethinylestradiol-induced cholestasis by preventing the accumulation of bile acids and salts in hepatocytes via induction of MRP2 (7, 8). The gene discussed is ABCC2; the disease is cholestasis.